Loading...
The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response.
Knothe, S Mutschler, V Rochlitzer, S Winkler, C Ebensen, T Guzman, C A Hohlfeld, J Braun, A Muller, M
Knothe, S
Mutschler, V
Rochlitzer, S
Winkler, C
Ebensen, T
Guzman, C A
Hohlfeld, J
Braun, A
Muller, M
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2011-06-06
Submitted date
Files
Loading...
Knothe et al_final.pdf
Adobe PDF, 241.81 KB
Other Titles
Abstract
One experimental approach for the treatment of allergic reactions is the stimulation of immunoregulatory NKT cells with the synthetic glycolipid αgalactosylceramide. For a first evaluation of the immunomodulatory potential of αGalCerMPEG a human in vitro allergy model was exploited. Acting as an adjuvant, the glycolipid induced an enhanced Th1-biased allergen-specific immune response of autologous lymphocytes. In a mouse model of allergic airway inflammation, αGalCerMPEG-activated NKT cells promoted a cytokine environment in the spleen, leading to priming of Th1 cells. The shift towards a Th1-dominated allergen-specific immune response thus might mediate the abrogation of allergic airway inflammation and thereby might provide a valid option for therapeutic intervention.
Citation
The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response. 2011, 29 (25):4249-55 Vaccine
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1873-2518